KYMR Earnings Prediction
The chart below shows how KYMR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KYMR sees a -1.35% change in stock price 10 days leading up to the earnings, and a +5.07% change 10 days following the report. On the earnings day itself, the stock moves by +1.17%. This data can give you a slight idea of what to expect for the next quarter's release.
KYMR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.74M
-20.88%
-85.42%
Gross Margin
--
--
--
Operating Margin
-1927.93%
58.50%
871.05%
Net Margin
-1670.33%
49.38%
918.62%
EPS
-0.82
-8.89%
41.38%
No Data Available
KYMR Earnings Analysis
Kymera Therapeutics, Inc. Common Stock Corporation (KYMR.O) Earnings Conference Call
Positive
Phase 1 Study Initiation: We have started the Phase 1 study of KT-621, our first-in-class oral STAT6 degrader, accelerating the path to the clinic given our recent increased focus of resources and capital that we're redirecting towards our growing immunology pipeline.
STAT6 Degrader Efficacy: We have shown in preclinical species that a STAT6 degrader like KT-621 can block IL-4 and 13 similarly or even more potently than an upstream biologics like dupilumab in both cellular and in vivo models.
Strong Cash Position: We ended the quarter with $911 million of cash on our balance sheet, providing a cash runway to mid-2027 and through several inflection points across our pipeline.
Funding Milestone Achieved: We raised a total of approximately $600 million in just 2024, enabling us to have cash into mid-2027 and through several inflection points across our pipeline.
Clinical Activity and Advancement: We have demonstrated a robust clinical activity across different tumor types, completing Phase 1 enrollment, and we have made the decision that we will only advance KT-333, our STAT3 degrader, and KT-253, our MDM2 degrader, beyond Phase 1 with a partner.
Negative
Revenue Decline Reported: In the third quarter of 2024, Kymera reported a revenue of only $3.7 million, which is significantly lower than expected, indicating a decline in financial performance.
R&D and SG&A Spending: Combined spending on R&D and SG&A was $61 million in the quarter, down about 2% sequentially from the previous quarter, reflecting tighter cost management amid declining revenues.
Cash Reserves Reliance: The company ended the quarter with $911 million in cash, which, while substantial, indicates a reliance on existing cash reserves due to low revenue generation.
Clinical Advancement Concerns: Kymera's focus on the KT-621 program has not yet translated into significant clinical advancements, raising concerns about the effectiveness of their product pipeline.
Phase 1 Study Challenges: The ongoing Phase 1 study for KT-621 has not yet yielded any promising results, which could hinder future investment and development opportunities.
KYMR FAQs
How does KYMR typically perform around its earnings report dates?
Is Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KYMR Earning Call Sentiment
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
KYMR.O
-0.7%Positive
The earnings call presents mixed signals: strong financial health with a substantial cash runway and recent capital raise, yet declining revenue and increased R&D expenses. The Q&A highlights strategic focus on immunology, but uncertainty in oncology and potential clinical risks. No new partnerships were announced, and there's a lack of clarity in management's responses. The market cap indicates moderate volatility, leading to a 'Neutral' prediction.
